IC
ICICI Prudential Nifty Pharma Index Fund Direct Growth
Latest NAV
+21.21% 1Y
Sign In to Add to Portfolio
Benchmark: Nifty Pharma TRI
Expense ratio
0.52%
AUM
₹157 Cr
Min SIP
₹1,000
Min lump sum
₹1,000
1Y
+21.21%
3Y (ann.)
+19.55%
5Y (ann.)
+0.00%
Launched
Dec 2022
Where the NAV sits & how risky it is
₹20.37
52-week range
at 85%
₹20.37
Low 02 Feb 2026₹16.65
High 31 Aug 2026₹21.06
Risk level
Very High
Low
Very high
NAV history
20 Dec 2022
Since inception
01 Oct 2026
Returns by period
1W
-2.66%
1M
-1.82%
3M
+4.63%
6M
+19.68%
1Y
+21.21%
3Y
+19.55%
5Y
+0.00%
3Y and 5Y returns are annualised.
Return calculator
You invest
—
Est. gain
—
Est. value
—
Invested Gain
Invested
Projected value
min SIP ₹1,000
Estimate only. It assumes the selected past return repeats every year; 3Y and 5Y figures are taken as annualised. Actual returns vary and are not guaranteed.
Where your money goes
AS OF 31 MAY 2026
Equity 99.50%
Cash & other 0.99%
Sector split
Country split
Top 5 hold 54.7%
Top 10 hold 77.7%
20 equity holdings
Equity holdings
| # | Holding | Sector | Country | Weight | YTD |
|---|---|---|---|---|---|
| 1 | Sun Pharmaceutical
INE044A01036 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
21.33%
|
+4.52% |
| 2 | Divis Laboratories
INE361B01024 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
9.48%
|
+3.85% |
| 3 | Dr Reddys Laboratories
INE089A01031 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
8.89%
|
+0.02% |
| 4 | Cipla
INE059A01026 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
8.83%
|
-8.03% |
| 5 | Lupin
INE326A01037 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
6.16%
|
+6.53% |
| 6 | Laurus Labs
INE947Q01028 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
5.93%
|
+25.17% |
| 7 | Torrent Pharmaceuticals
INE685A01028 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
5.16%
|
+16.93% |
| 8 | Aurobindo Pharma
INE406A01037 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
4.46%
|
+22.87% |
| 9 | Glenmark Pharmaceuticals
INE935A01035 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
3.83%
|
+5.37% |
| 10 | Alkem Laboratories
INE540L01014 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
3.60%
|
-2.98% |
About this scheme
The objective of the Scheme is to invest in companies whose securities are included in Nifty Pharma Index and subject to tracking errors, to endeavor to achieve the returns of the above index. This would be done by investing in all the stocks comprising the Nifty Pharma Index in the same weightage that they represent in Nifty Pharma Index. However, there is no assurance or guarantee that the investment objective of the scheme shall be achieved.
Fund manager(s): Nishit Patel, Ashwini Bharucha
Exit load: No charges for withdrawal
Scheme snapshot
VR Rating
MS Rating
Plan
Growth
Type
DIRECT
Inception
15 Dec 2022
Lump-sum min
₹1,000
SIP
Purchase
Switch
STP
SWP
Similar schemes
RANKED BY 1Y RETURN
SBI Silver ETF FoF Direct Growth
1▲ 29.1 pts ahead of this fund
Kotak Silver ETF FoF Direct Growth
2▲ 28.3 pts ahead of this fund
Axis Silver FoF Direct Growth
3▲ 27.6 pts ahead of this fund
ICICI Prudential Strategic Metal and Energy Equity FoF Direct Growth
4▲ 27.6 pts ahead of this fund
DSP Silver ETF FoF Direct Growth
5▲ 27.5 pts ahead of this fund
Zerodha Silver ETF FoF Direct Growth
6▲ 27.5 pts ahead of this fund